Medtronic plc (MDT) today announced U.S. Food and Drug Administration (FDA) approval of the InterStim(TM) smart programmer for use with the InterStim system, which provides sacral neuromodulation therapy for the treatment of overactive bladder (OAB), chronic fecal incontinence (FI) and non-obstructive urinary retention.
Linnea Burman, vice president:
The new smart programmer streamlines multiple devices into a single, intuitive, touch screen Samsung mobile device and enables clinicians to personalize each patient’s care and allows patients to manage their therapy simply and discreetly.
OAB and FI are treatable, extremely common and embarrassing conditions. More than 37 million adults in the United States – almost one in six – suffer from OAB and nearly 20 million Americans – about one in 12 – have bowel incontinence.1-4